» Articles » PMID: 18048036

Modulation of Immune Response by Head Injury

Overview
Journal Injury
Publisher Elsevier
Specialty Emergency Medicine
Date 2007 Dec 1
PMID 18048036
Citations 193
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the fact that traumatic brain injury (TBI) is a silently growing epidemic, we are yet to understand its multifaceted pathogenesis, where various cellular pathways are initiated in response to both the primary mechanical insult and secondary physiologically mediated injury. Although the brain has traditionally been considered an immunologically privileged site, evidence to the contrary exists in studies of central nervous system (CNS) pathology, in particular TBI. Transmigration of leukocytes following blood brain barrier (BBB) disruption results in activation of resident cells of the CNS, such as microglia and astrocytes, to possess immunological function. Both infiltrating peripheral immune cells and activated resident cells subsequently engage in the intrathecal production of cytokines, important indicators of the presence of neuroinflammation. Cytokines can either promote this neurotoxicity, by encouraging excitotoxicity and propagating the inflammatory response, or attenuate the damage through neuroprotective and neurotrophic mechanisms, including the induction of cell growth factors. Certain cytokines perform both functions, for example, interleukin-6 (IL-6). This review article discusses the notion that the inflammatory response to TBI is no longer a peripherally mediated phenomenon, and that the CNS significantly influences the immunological sequence of events in the aftermath of injury.

Citing Articles

Effect of statins on neurological functional outcomes in critically ill adult patients with traumatic brain injury: a systematic review and meta-analysis.

Veillette C, Umana M, Gagnon M, Costerousse O, Zarychanski R, McAuley D BMJ Open. 2025; 15(2):e091971.

PMID: 39971597 PMC: 11840907. DOI: 10.1136/bmjopen-2024-091971.


The Relevance and Implications of Monoclonal Antibody Therapies on Traumatic Brain Injury Pathologies.

Wang P, Okada-Rising S, Scultetus A, Bailey Z Biomedicines. 2025; 12(12.

PMID: 39767605 PMC: 11672875. DOI: 10.3390/biomedicines12122698.


Hydrogel in the Treatment of Traumatic Brain Injury.

Li S, Xu J, Qian Y, Zhang R Biomater Res. 2024; 28:0085.

PMID: 39328790 PMC: 11425593. DOI: 10.34133/bmr.0085.


Microglial process convergence onto injured axonal swellings, a human postmortem brain tissue study.

Logan-Wesley A, Gorse K, Lafrenaye A Sci Rep. 2024; 14(1):21369.

PMID: 39266604 PMC: 11392954. DOI: 10.1038/s41598-024-71312-7.


Microglial process convergence onto injured axonal swellings, a human postmortem brain tissue study.

Logan-Wesley A, Gorse K, Lafrenaye A Res Sq. 2024; .

PMID: 39149456 PMC: 11326398. DOI: 10.21203/rs.3.rs-4713316/v1.